We are very fortunate to have a specialized Scientific Advisory Board (SAB) which combined has: a) published more than 500 peer-reviewed scientific publications; b) participated in over 50 FDA clinical trials; and c) has invented/brought to market 5 new drugs.
The SAB was chosen based on expertise from basic research to clinical trials, to commercial implementation. Basic cancer immunology researchers, Dr. Davorka Messmer worked with the discoverer of the dendritic cell, Dr. Ralph Steinman at Rockefeller University, and since has been a prolific researcher identifying many of the key elements which the innate immune system uses in fighting cancer. Dr. Mehmet Kilinic’s basic research is focused on how cellular stress and viral infections can be used to selectively kill tumors and induce immunity subsequent to infection.
In translational research, Dr. Michael Agadjanyan was one of the original inventors of the DNA vaccine, which is utilized by numerous companies in cancer immunology clinical trials. Additionally, Dr. Agadjanyan has developed numerous tumor vaccines and immunotherapeutic approaches which are currently being translated into clinical trials.
Dr. Boris Minev was one of the key developers of Melacine, the first tumor vaccine to receive marketing approval in the Western Hemisphere. Dr. Minev is currently working with viruses that preferentially kill tumor cells, having taken this approach into Phase II oncology trials.
Dr. Thomas Ichim is inventor of a new stem cell, which entered clinical trials and purchased by the NYSE-traded company, Intrexon. Additionally Dr. Ichim is inventor on over 50 patents and patent applications related to cancer immunotherapy. ValloVax, the first cancer blood vessel targeting vaccine, a “second generation” Govallo vaccine was invented by Dr. Ichim.